Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.

Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas VR, Wolff AM, Fraser JS, Collisson EA, McCoach CE, Camidge DR, Pacheco J, Bazhenova L, Li T, Bivona TG, Blakely CM.

Clin Cancer Res. 2020 Jan 15;26(2):439-449. doi: 10.1158/1078-0432.CCR-19-1667. Epub 2019 Sep 23.

PMID:
31548343
2.

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.

Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG.

Nat Genet. 2017 Dec;49(12):1693-1704. doi: 10.1038/ng.3990. Epub 2017 Nov 6.

3.

Inactivation of Capicua drives cancer metastasis.

Okimoto RA, Breitenbuecher F, Olivas VR, Wu W, Gini B, Hofree M, Asthana S, Hrustanovic G, Flanagan J, Tulpule A, Blakely CM, Haringsma HJ, Simmons AD, Gowen K, Suh J, Miller VA, Ali S, Schuler M, Bivona TG.

Nat Genet. 2017 Jan;49(1):87-96. doi: 10.1038/ng.3728. Epub 2016 Nov 21.

4.

Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3Cβ(D1067V) kinase domain mutation.

Pazarentzos E, Giannikopoulos P, Hrustanovic G, St John J, Olivas VR, Gubens MA, Balassanian R, Weissman J, Polkinghorn W, Bivona TG.

Oncogene. 2016 Mar 3;35(9):1198-205. doi: 10.1038/onc.2015.173. Epub 2015 May 18.

PMID:
25982275
5.

Hyperglycemia impairs atherosclerosis regression in mice.

Gaudreault N, Kumar N, Olivas VR, Eberlé D, Stephens K, Raffai RL.

Am J Pathol. 2013 Dec;183(6):1981-1992. doi: 10.1016/j.ajpath.2013.08.019. Epub 2013 Oct 8.

6.

Inducible ApoE gene repair in hypomorphic ApoE mice deficient in the low-density lipoprotein receptor promotes atheroma stabilization with a human-like lipoprotein profile.

Eberlé D, Luk FS, Kim RY, Olivas VR, Kumar N, Posada JM, Li K, Gaudreault N, Rapp JH, Raffai RL.

Arterioscler Thromb Vasc Biol. 2013 Aug;33(8):1759-67. doi: 10.1161/ATVBAHA.112.300605. Epub 2013 Jun 20.

7.

Macrophage-specific apoE gene repair reduces diet-induced hyperlipidemia and atherosclerosis in hypomorphic Apoe mice.

Gaudreault N, Kumar N, Olivas VR, Eberlé D, Rapp JH, Raffai RL.

PLoS One. 2012;7(5):e35816. doi: 10.1371/journal.pone.0035816. Epub 2012 May 14.

8.

Apolipoprotein E4 domain interaction accelerates diet-induced atherosclerosis in hypomorphic Arg-61 apoe mice.

Eberlé D, Kim RY, Luk FS, de Mochel NS, Gaudreault N, Olivas VR, Kumar N, Posada JM, Birkeland AC, Rapp JH, Raffai RL.

Arterioscler Thromb Vasc Biol. 2012 May;32(5):1116-23. doi: 10.1161/ATVBAHA.112.246389. Epub 2012 Mar 22.

9.

ApoE suppresses atherosclerosis by reducing lipid accumulation in circulating monocytes and the expression of inflammatory molecules on monocytes and vascular endothelium.

Gaudreault N, Kumar N, Posada JM, Stephens KB, Reyes de Mochel NS, Eberlé D, Olivas VR, Kim RY, Harms MJ, Johnson S, Messina LM, Rapp JH, Raffai RL.

Arterioscler Thromb Vasc Biol. 2012 Feb;32(2):264-72. doi: 10.1161/ATVBAHA.111.238964. Epub 2011 Nov 3.

Supplemental Content

Loading ...
Support Center